The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer remain a ...

Strong Q1 2025 results for Evaxion (EVAX) with a boosted cash position, progress in oncology & infectious diseases, and key milestones ahead.

Evaxion AS (EVAX) reports a significant cash increase and positive vaccine data, despite facing macroeconomic challenges.

How CD4+ T cells respond to Chikungunya virus may trigger long-lasting joint pain, mimicking autoimmune disease long after ...

Historically, the presence of measurable disease has been considered essential to stimulate CAR T-cell expansion and persistence. However, the kinetics of CAR T cells in patients achieving complete ...

There is no highly effective vaccine against tuberculosis (TB), which remains an infection of global concern. Charles ...

CHIKV can trigger long-term joint pain that mimics autoimmune diseases like rheumatoid arthritis, potentially due to ...

By studying Chikungunya virus, scientists shed light on how immune responses to viral infections may lead to persistent symptoms of autoimmune disease.

Chikungunya virus (CHIKV) is a mosquito-borne pathogen that has been identified in more than 110 countries around the world.

Chikungunya virus (CHIKV) is a mosquito-borne pathogen that has been identified in more than 110 countries around the world. The virus ...

Autoimmune destruction of pancreatic β cells results in type 1 diabetes (T1D), with pancreatic immune infiltrate representing a key feature in this process. However, characterization of the ...

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...